Patisiran (Onpattro)

Covered: Onpattro (patisiran) is covered for adults (≥18) with genetically confirmed hereditary transthyretin‑mediated amyloidosis who have symptomatic polyneuropathy; it is not covered for patients <18 or without genetic confirmation or symptomatic disease. Key requirements: patient must have trialed or be receiving ≥1 systemic agent for neuropathic symptoms (gabapentin-type, duloxetine, or a tricyclic antidepressant), the drug must be prescribed by or in consultation with a neurologist/geneticist/amyloidosis specialist, documentation must include genetic test results, clinical neuropathy and medication history, weight and infusion records, dosing is 0.3 mg/kg IV every 3 weeks (max 30 mg), and approvals are limited to 12 months with documentation for reauthorization.

"Patient must be at least 18 years of age (i."

Sign up to see full coverage criteria, indications, and limitations.